Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Internal medicine journal (Print)

• Publication date

  2016-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/imj.13085PMID 27040159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comorbidities against Quality Control of VKA Therapy in Non-Valvular Atrial Fibrillation: A French National Cross-Sectional Study

  2015influential reference
• National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation

  2014influential reference
• The Economic Burden to Medicare of Stroke Events in Atrial Fibrillation Populations With and Without Thromboprophylaxis

  2014cited by this paper
• Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials

  2014cited by this paper
• Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation

  2014cited by this paper
• A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants

  2014cited by this paper
• Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

  2014cited by this paper
• Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial

  2013influential reference
• Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups

  2013cited by this paper
• Oral anticoagulant therapies: balancing the risks.

  2013cited by this paper
• The quality of international normalised ratio control in southern Tasmania

  2013influential reference
• Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

  2012cited by this paper
• New anticoagulants in atrial fibrillation: an update for clinicians

  2012cited by this paper
• Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.

  2011cited by this paper
• Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and infuential factors-.

  2011influential reference
• Abstract 16179: Cost-effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation

  2010cited by this paper
• Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review

  2008cited by this paper
• Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

  2008cited by this paper
• Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)

  2007influential reference
• Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

  2007cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting.

  2006cited by this paper
• Effect of study setting on anticoagulation control: a systematic review and metaregression.

  2006cited by this paper
• Health literacy and anticoagulation-related outcomes among patients taking warfarin

  2006cited by this paper
• Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study

  2005cited by this paper
• Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range

  2003cited by this paper
• AN ANALYSIS OF THE LOWEST EFFECTIVE INTENSITY OF PROPHYLACTIC ANTICOAGULATION FOR PATIENTS WITH NONRHEUMATIC ATRIAL FIBRILLATION

  2000cited by this paper
• An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.

  1996cited by this paper
• A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

  1993cited by this paper
• Pharmaceutical benefits scheme.

  1986cited by this paper
• O R I G I N a L C L I N I C a L I N V E S T I G a T I O N Open Access

  year unknowncited by this paper

• Direct oral anticoagulant prescribing for atrial fibrillation: an Australian tertiary centre experience of ischaemic stroke complication.

  2026cites this paper
• Effect of the quality of anticoagulation on the risk of stroke, thrombotic events, hemorrhagic events, and death in patients with nonvalvular atrial fibrillation on acenocoumarol in Real-World Data

  2024cites this paper
• Anticoagulation Quality of Warfarin and the Role of Physician–Pharmacist Collaborative Clinics in the Treatment of Patients Receiving Warfarin: A Retrospective, Observational, Single-Center Study

  2021cites this paper
• Factors Affecting Quality of Anticoagulation Achieved with Warfarin as Thromboprophylaxis for Stroke Prevention in Non-valvular Atrial Fibrillation

  2021cites this paper
• Physician–Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development

  2021cites this paper
• Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control.

  2021cites this paper
• Assessment of the influence of sex on oral anticoagulation control in patients taking coumarin derivatives: a systematic review protocol.

  2020cites this paper
• The SAMe–TT2R2 score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia

  2020cites this paper
• The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation

  2019cites this paper
• Anticoagulation with Warfarin: Roles of Adherence, Social Support and Illness Perception

  2019cites this paper
• Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia

  2018cites this paper
• Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review

  2018cites this paper
• Warfarin control in patients transitioning to warfarin after non-vitamin K oral anticoagulant (NOAC) therapy

  2018cites this paper
• Factors influencing warfarin control in Australia and Singapore.

  2017cites this paper
• A High HASBLED Score Identifies Poor Warfarin Control in Patients Treated for Non‐Valvular Atrial Fibrillation in Australia and Singapore

  2017cites this paper
• HAS‐BLED Predicts Warfarin Control in Australian Patients treated for Deep Vein Thrombosis

  2017cites this paper
• The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study

  2016cites this paper
• Élaboration et évaluation d’un protocole de coopération pluriprofessionnel visant à améliorer la prise en charge des patients sous AVK dans un territoire donné

  2016cites this paper
• Antithrombotic therapy in patients with atrial fibrillation : the Tasmanian experience

  2016influential citation